Dosimetric outcomes in prostate brachytherapy: Is downsizing the prostate with androgen deprivation necessary?

Brachytherapy

Volumn 8, Issue 3, 2009, Pages 304-308

  Gibbons, Erin P ^a,b   Jacobs, Bruce L ^a   Smith, Ryan P ^a   Beriwal, Sushil ^a   Krishna, Komanduri ^a   Benoit, Ronald M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgen deprivation; Brachytherapy; Prostate cancer; Prostate volume

Indexed keywords

IODINE 125; PALLADIUM 103;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; DOSIMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES;

EID: 67651056218     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2008.11.009     Document Type: Article

References (24)

1. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
2. Prestidge B.R., Prete J.J., Buchholz T.A., et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 40 (1998) 461-465
3. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendation for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
4. 3: dosimetric analysis of implant quality. Int J Radiat Oncol Biol Phys 46 (2000) 1199-1204
5. Wilson S. Downsizing and prostate cancer. Rev Urol 6 Suppl 7 (2004) S19-S24
6. Lee W.R. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology 60 3 Suppl. 1 (2002) 39-44
7. Gibbons E.P., Smith R.P., Beriwal S., et al. Overcoming pubic arch interference with free hand needle placement in men undergoing prostate brachytherapy. Brachytherapy. 8 (2009) 74-78
8. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendation for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 46 (2000) 221-230
9. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
10. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
11. Quan A.L., Ciezki J.P., Reddy C.A., et al. Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate. Urology 68 (2006) 1237-1241
12. Kucway R., Vicini F., Huang R., et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 167 (2002) 2443-2447
13. Potters L., Torre T., Ashley R., et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 18 (2000) 1187-1192
14. Ebara S., Manabe D., Kobayashi Y., et al. The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer. Acta Med Okayama 61 (2007) 335-340
15. Beyer D.C., McKeough T., and Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1299-1305
16. Sylvester J., Blasko J., Grimm P., et al. 125-Iodine/103-Palladium brachytherapy with or without neoadjuvant androgen ablation for early stage prostate cancer. Int J Radiat Oncol Biol Phys 48 (2000) 310-311
17. Sylvester J, Blasko JC, Grimm P, et al. The impact of short course androgen ablation on the biochemical progression-free survival of high-risk, localized prostate cancer patients managed with a combination of permanent interstitial brachytherapy and external beam radiation therapy. J Brachyther Int 2001. In press.
18. Merrick G.S., Butler W.M., Wallner K.E., et al. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 68 (2007) 34-40
19. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 453-460
20. 125I prostate brachytherapy. Brachytherapy 1 (2002) 131-137
21. Hinerman-Mulroy A., Merrick G.S., Butler W.M., et al. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 59 (2004) 1367-1382
22. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 47 (2000) 121-128
23. Stock R.G., Kao J., and Stone N.N. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 165 (2001) 436-439
24. Potters L., Torre T., Fearn P.A., et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1235-1242